Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows even greater efficacy in ongoing trials, with weight losses reaching 22% in certain patient subgroups
This dual action provides enhanced appetite suppression and metabolic effects, leading to greater weight loss compared to Semaglutides single-receptor action
Clinical trials and real-world data reveal that side effect frequency and severity vary considerably between individuals, making personalized medicine an important consideration when choosing between these therapies
Microdosing seems to be overwhelmingly targeted to women who either dont qualify for prescription GLP-1s, and/or have very little to no weight to lose (which is why they dont qualify for the rx in the first place)
Tussing-Humphreys LM, Nemeth E, Fantuzzi G, Freels S, Holterman AX, Galvani C, et al
This bruising tends to be on the upper cheek and lower eyelid junction area and thats usually an inch or two below where the incisions are